Sareum Holdings Plc SAR
There have not been any declared dividends recently.
|Summary||Previous dividend||Next dividend|
Enter the number of Sareum Holdings Plc shares you hold and we'll calculate your dividend payments:
Sign up for Sareum Holdings Plc and we'll email you the dividend information when they declare.
Add Sareum Holdings Plc to receive free notifications when they declare their dividends.
Your account is set up to receive Sareum Holdings Plc notifications.
|Status||Type||Decl. date||Ex-div date||Pay date||Decl. Currency||Forecast amount||Decl. amount||Accuracy|
|There are no Sareum Holdings Plc dividends.|
|2021||Sign Up Required|
Sareum Holdings Plc Optimized Dividend Chart
About Sareum Holdings Plc
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
- Pharmaceuticals & Biotechnology
- United Kingdom
- Share Price
- £0.07 (yesterday's closing price)
- Shares in Issue
- 3,370 million
- Market Cap
- Market Indices